Yep you are correct ymav4294. The data on progression free survival(PFS) is the key to efficacy of CVac. The ongoing CAN003 data for the 63patients and the Can004 will tell us the extent of efficacy. The ICS as you say came out great as was expected but in a formal way supported by specific data that will be accepted by the scientific world and the authorities in drug development.
cheers
Ann: CAN-003 INTERIM ANALYSIS PRESENTATION , page-19
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |